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Abstract
Pre-existing immunity against adeno-associated virus (AAV) remains a major challenge facing the clinical use of systemic
administration of recombinant AAV vectors for the treatment of genetic and acquired diseases using gene therapy. In this
study, we evaluated the potential of bortezomib (marketed under trade name Velcade) to abrogate a pre-existing immunity
to AAV in mice, thereby allowing subsequent transduction by a recombinant AAV vector of the same serotype. We
demonstrate that bortezomib efficiently reduces AAV-specific IgG titres and moderates the cytotoxic T cell response in mice
that have a pre-existing immunity to AAV2/8. Significant depletion of AAV2/8-specific IgG-producing plasma cells in
secondary lymphoid organs and bone marrow was observed. However, this inhibition of the immune response by
bortezomib was insufficient to allow subsequent re-infection with a recombinant AAV vector of a similar serotype. We show
that this shortcoming is probably due to the combination of residual antibody levels and the inability of bortezomib to
completely deplete the memory B cells that are re-activated in response to a repeated infection with a recombinant AAV
vector. Taken together, the results of this study argue for the use of immunosuppressive therapies that target both plasma
and memory B cells for the efficient elimination of pre-existing immunity against AAV2/8 vectors.
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Introduction
Recombinant adeno-associated viral (AAV) vectors have been
extensively studied as delivery systems for gene therapy treatment
in a variety of disease indications. This vector platform is being
used in several clinical trials for the treatment of a number of
genetic diseases, including haemophilia B, a-1-antitrypsin defi-
ciency, Duchenne muscular dystrophy, Leber’s congenital amau-
rosis, leukodystrophies, age-related macular degeneration and
Parkinson’s disease [1–5]. This progress to clinical trials has
stemmed from pre-clinical studies showing that recombinant AAV
vectors transduce a variety of cell types, facilitate high-level and
long-term gene expression and are relatively innocuous [1–5].
Although certain characteristics of AAV make it a promising
gene transfer vector, several challenges limit its clinical use.
Foremost, there is a prevalence of pre-existing immunity to the
viral capsids in the general population [6]. This pre-existing
immunity to AAV may be due to endemic infection by the virus
early in childhood [6]. To alleviate this pre-existing immunity,
capsid proteins have been modified to exhibit a lower immuno-
genicity profile, and immunosuppressive agents have been
deployed to dampen the immune response [7,8]. The immuno-
suppressive agents that have been evaluated are primarily agents
that inhibit T cell activation/survival and inhibit antigen
presentation on major histocompatibility (MHC) molecules to T
cells. The agent bortezomib (Velcade) [9] has been used
successfully in several pre-clinical studies. Bortezomib, a specific
inhibitor of the 26 S proteasome, has been approved as a
treatment for patients with multiple myeloma [9]. In pre-clinical
studies, when bortezomib was administered simultaneously with a
recombinant AAV vector, it reportedly increased the efficacy of
gene delivery [10–12]. In these studies, bortezomib inhibited
cytotoxic CD8
+ T cell responses through its activity against the
26 S proteasome system, which prevented antigen presentation on
MHC class I molecules to CD8
+ T cells [10].
Recently, bortezomib has been shown to exhibit additional
inhibitory effects on the immune system. In a pre-clinical animal
model of systemic lupus erythematosus (SLE), bortezomib was
highly efficient at depleting antibody-producing cells in secondary
lymphoid organs and bone marrow, thereby limiting the
progression of the disease [13]. It was suggested that this effect
was due to the susceptibility of terminally differentiated B cells
(which produce large amounts of secreted antibody) to proteasome
inhibition. This increased susceptibility of antibody-producing cells
to bortezomib was due to their dependence on the unfolded
protein response that eliminates misfolded proteins, which was
blocked by proteasome inhibition [13–15]. Based on these
observations, we argue that this property of bortezomib might
be advantageous in promoting the efficacy of AAV-mediated gene
therapy. Similar to the antibody-producing cells in SLE,
bortezomib might act to deplete antibody-producing cells that
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enabling increased gene transduction activity. In this study, we
demonstrate that bortezomib lowers pre-existing anti-AAV
antibody levels in mice by reducing the number of plasma cells
in secondary lymphoid organs and bone marrow. However, this
reduction is insufficient to support a subsequent infection by a
recombinant AAV2/8 vector. This inability to support a
subsequent infection is probably due to the combination of
residual antibody levels after bortezomib treatment and the
inability of bortezomib to influence memory B cell populations
that are re-activated in response to a secondary challenge by the
recombinant AAV2/8 serotype vector.
Materials and Methods
Animals
Ethics Statement: Procedures involving mice were reviewed and
approved by Genzyme Corporation’s Institutional Animal Care
and Use Committee (protocol number 10-0224-01) following
guidelines established by the Association for Assessment of
Accreditation of Laboratory Animal Care. The review board
specifically approved all the studies (identification numbers 10-
00605 and 10-01005) reported in this manuscript. Wild-type male
C57BL/6 mice between the ages of 6 and 10 weeks were obtained
from Jackson Laboratories (Bar Harbor, ME). All animal
experiments were approved by Genzyme Corporation’s Institu-
tional Animal Care and Use Committee. At least 7 animals per
group were used in each experiment.
Recombinant AAV Vectors
Recombinant AAV2/8 serotype vectors were generated and
titred at Genzyme Corporation, as described previously [16,17].
Two AAV2/8 vectors were used in the studies: (1) AAV2/8-EV
(an empty vector) harbouring a human cytomegalovirus promoter
but no transgene and (2) AAV2/8-DC190-alphaGal designed to
express the lysosomal enzyme a-galactosidase A under the
transcriptional control of a liver-specific promoter (DC190)
[16,17]. For all studies, the mice were injected intravenously with
5610
11 viral particles via the tail vein.
Bortezomib Treatment
Male mice were infected with AAV2/8-EV as described above.
At four weeks post-administration of the virus, the animals were
treated with various doses of bortezomib (Selleck Chemicals,
Houston, TX) administered by intravenous injection twice weekly
for 20 weeks. At the end of the 20-week period (24 weeks post-
infection with AAV2/8-EV), the mice were administered 5610
11
viral particles of AAV2/8-DC190-alphaGal three days after the
final treatment with bortezomib. Serum levels of a-galactosidase A
were monitored starting at one and two weeks post-challenge. At
four weeks post-challenge, the mice were sacrificed, and immune
responses were evaluated, as described below.
Flow Cytometry and Measurement of Cytokine Levels
Fluorescently labelled antibodies were obtained from either
eBioscience (San Diego, CA) or BD Biosciences (San Jose, CA).
Flow cytometry was performed by staining 10
6 cells that were
suspended in PBS containing 1% bovine serum albumin. Fc
receptors were blocked prior to staining using unlabelled blocking
antibody. Cells were stained with a combination of fluorescently
labelled anti-CD3, CD4, CD8, CD44, CD27, CD19, CD38, and
CD138 antibodies for 20 minutes at 4uC, thoroughly washed and
analysed using an LSRII cytometer (BD Biosciences, San Jose,
CA) and FlowJo version 7.6.4 software (Treestar, Eugene, OR).
Mononuclear cells prepared from spleens were reactivated by
being exposed to various amounts of recombinant AAV2/8-EV
vectors (10, 1, and 0.1 mg/ml capsid protein, respectively) in vitro in
Dulbecco’s modified Eagle’s medium with 10% fetal bovine
serum. In the figures, results using 10 mg/ml capsid protein are
shown. At three days post-activation, the cells were stained as
described above, the supernatants were collected and the levels of
interleukin-2 and interferon-c were measured using an enzyme-
linked immunosorbent assay according to the manufacturer’s
instructions (eBioscience, San Diego, CA).
Measurement of AAV2/8-specific IgG, Total IgG and a-
galactosidase A Levels
Levels of AAV2/8-specific IgG were measured by coating high-
binding enzyme immunoassay plates with AAV2/8-EV. Serum
samples were titrated onto the coated plates and developed with
horseradish peroxidase-conjugated goat anti-mouse IgG (Sigma-
Aldrich, St. Louis, MO). Titres were determined as the lowest
dilution of serum at which the OD was equal to or greater than
0.1. The levels of total IgG in serum and culture supernatants were
measured by coating high-binding enzyme immunoassay plates
with unlabelled rabbit anti-mouse IgG (Novus Biologicals,
Littleton, CO), and the plates were developed using horseradish
peroxidase-conjugated donkey anti-mouse IgG (Novus Biologicals,
Littleton, CO). Serum a-galactosidase A levels were measured as
described previously [17]. For the immunohistochemical studies,
livers were harvested, sectioned and fixed in 4% paraformalde-
hyde. Paraffin-embedded sections (5 mm) were stained with rabbit
anti-alpha galactosidase A antibody [16] followed by HRP-
labelled anti-rabbit IgG (Sigma-Aldrich, St. Louis, MO).
Statistical Analysis
Student’s t-test was used to compare groups of data. A p value of
less than 0.05 was considered significant. Multiple groups of data
were compared using one-way ANOVA.
Results
Bortezomib is Effective in Reducing Anti-recombinant
AAV2/8 Vector Antibody Levels in Mice
Bortezomib is effective in reducing the levels of antibody-
producing cells as illustrated by its ability to lower autoantibody
titres in a murine model of systemic lupus erythematosus [13].
Consequently, we tested whether a bortezomib-mediated reduc-
tion of antibody-producing cells would lead to a similar abatement
of humoral immunity to recombinant AAV vectors. Mice were
injected systemically with an empty AAV2/8 pseudotyped vector
(containing no transgene) [16,18] and were treated (by intravenous
injection) with various amounts of bortezomib four weeks later.
This timepoint was chosen as antibody levels steadily rise and
immunological memory is formed in the four weeks post initial
infection. Indeed, during the intervening 4-week period, a
significant increase in anti-AAV2/8 antibodies was observed
(Figure 1). Mice that were administered 1 mg/kg bortezomib did
not exhibit an increase in antibody titre, and importantly,
antibody levels were reduced to a steady state following an
additional 8 weeks of treatment (Figure 1a). An 8- to 10-fold
reduction in anti-AAV IgG levels was noted in the treated animals;
however, these animals retained significant levels of antibodies.
The observed reduction in AAV-specific IgG levels was correlated
with a lower level of total IgG in the sera, suggesting that
bortezomib inhibited all IgG antibody-producing cells (Figure 1b).
The administration of lower doses (0.2 and 0.04 mg/kg) of
bortezomib did not alter the profile of anti-AAV titres from that of
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was observed in ,15% (1/7) of the animals that were treated with
1 mg/kg bortezomib, indicating that the drug displays a narrow
therapeutic window in mice as a strategy to lower pre-existing anti-
AAV immunity.
Bortezomib Reduces the Number of CD138
+ Plasma Cells
but not Other B or T Cell Populations
To determine the basis of the bortezomib-mediated reduction in
anti-AAV IgG levels, B and T cell populations were analysed
following termination of the in vivo phase of the studies. B cells are
capable of secreting IgG at several developmental stages of their
life cycle and require help from T cells for isotype switching [19].
To elucidate the specific juncture at which bortezomib may
function, the percentage of various B and T cell populations in the
spleen and bone marrow (terminally differentiated plasma cells
home to niches in the bone marrow for long term survival [20]) of
the mice was evaluated. Splenic and bone-marrow cell populations
were incubated with AAV for three days in vitro to enrich for
CD138
+ cells. We elected using this method due to the fact that
CD138
+ cells constitute a very rare population in bone marrow
that is close to level of detection by flow cytometry. Bortezomib-
treated animals exhibited a significant decrease in the percentage
and absolute numbers of CD138
+ plasma cells in the spleen and
bone marrow (Figure 2a, left panel and Figure 2b, top row;
Figure 2c, left panel and Figure 2d, top row). Interestingly, no
other B cell population (e.g., splenic CD27
+ memory B cells and
CD19
+CD27
2CD138
2 non-memory/non-plasma cell B cells) was
significantly reduced (Figure 2a, right panel and Figure 2b, middle
and bottom rows; Figure 2c, right panel and Figure 2d, middle and
bottom rows). In the bone marrow, a small but statistically
significant decrease was detected in the percentage of CD27
+
B cells, but there was no decrease in the absolute number of
CD27
+ B cells (Figure 2c and 2d, middle row). These results are
congruent with studies by Neubert et al. [13] that demonstrated
that bortezomib treatment has little or no effect on B cell
populations in mice other than that on plasma cells.
T cell responses were evaluated by staining with anti-CD4, anti-
CD8 and anti-CD44 (to assess T-cell activation status) antibodies.
The response to in vitro reactivation was measured by assessing
cytokine production. Direct ex vivo staining of splenic and bone
marrow lymphocytes demonstrated differential effects on helper
and cytotoxic T cells, respectively (Figure 3). The percentage or
absolute number of CD4
+ helper T cells did not change (data not
shown). The activation status of the CD4
+ T cell population, as
assessed by CD44 expression, also remained unchanged (Figure 3a,
left panel and Figure 3b, top panel). Compared to the PBS-treated
controls, the percentage and absolute number of CD8
+ cytotoxic
T cells remained unchanged in the bortezomib-treated animals
(data not shown). However, there was a significant reduction in the
percentage of the CD44
high effector/memory CD8
+ T cell
population (Figure 3a, right panel and Figure 3b, bottom panel).
This finding is consistent with previous reports that bortezomib
has an inhibitory effect on cytotoxic T cell responses, presumably
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+ T cells requires protein
degradation by the 26 S proteasome [21,22].
T cells from bortezomib- and PBS-treated mice produced
similar levels of interleukin-2 following reactivation by AAV
(Figure 3c, left panel). However, there was a significant decrease in
the levels of the signature antiviral cytokine interferon-c in the
bortezomib-treated mice compared to the PBS-treated controls
(Figure 3c, right panel). This result was probably due to the
decrease in the number and percentage of the CD44
high fraction of
the CD8
+ T cell population, a major producer of this cytokine.
These data suggest that bortezomib inhibits the immune response
to AAV at the level of both plasma and CD8
+ T cells. However,
the effect of bortezomib on B cells is restricted to the terminally
differentiated CD138
+ plasma cell population; bortezomib does
not affect other B cell subpopulations.
Bortezomib-mediated Reduction of Pre-existing
Immunity to AAV is Ineffective in Negating a Humoral
Immune Response to a Subsequent Infection by a
Recombinant AAV Vector
A potential application for bortezomib is the depletion of pre-
existing anti-AAV antibodies such that the host is conducive to a
subsequent infection by a recombinant AAV vector of the same
serotype. To test this theory, mice were first administered an
empty viral vector (AAV2/8-EV) and were subsequently subjected
to treatment with bortezomib 4 weeks later (following the
appearance of anti-AAV antibodies) for 20 weeks. At the end of
this 20-week period, the mice were challenged systemically with a
recombinant AAV2/8 vector encoding a-galactosidase A (AAV2/
8-DC190-alphaGal). At week 24 post infection, serum anti-AAV
IgG titers were 1:64,000613,249 and 1:8,00061852 for the PBS-
and bortezomib-treated groups, respectively (Figure 1a and 4a). A
rapid and robust increase in anti-AAV-specific IgGs was observed
in both bortezomib- and PBS-treated (control) animals following
administration of AAV2/8-DC190-alphaGal (Figure 4a). The
levels of IgG peaked between 2 and 3 weeks post-infection and
remained undiminished at 8 weeks (Figure 4a). Previously naı ¨ve
mice infected with the AAV2/8-DC190-alphaGal vector showed
an increase in anti-AAV IgG levels with significantly slower
kinetics as compared to animals previously exposed to AAV2/8-
EV, indicating a primary immune response in the previously naı ¨ve
animals as compared to a memory response in the mice previously
exposed to AAV2/8-EV. The observed increase in IgG levels in
the animals previously exposed to AAV2/8-EV was probably from
the B cell populations that were unaffected by bortezomib
treatment and reactivated in response to the administration of
AAV2/8-DC190-alphaGal. Consistent with this theory was the
appearance of similar levels of total IgG levels in the PBS- and
bortezomib-treated animals and the fact the kinetics of the
increase in total IgG was similar between the PBS- and
bortezomib-treated animals (Figure 4b).
To determine whether the reduction in the levels of the pre-
existing anti-AAV antibodies mediated by bortezomib affected
gene transduction by AAV2/8-DC190-alphaGal, the levels of a-
galactosidase A in the serum were measured. No enzyme was
detected in the PBS- and bortezomib-treated mice (Figure 4b). In
contrast, mice that were naı ¨ve to any treatment showed
abundant expression of a-galactosidase A following the admin-
istration of AAV2/8-DC190-alphaGal (Figure 4c), and levels
were consistent with previous reports [16,17]. Immunohisto-
chemical staining for a-galactosidase A in liver sections showed
similar results (Figure 4d). Taken together, these data suggest that
despite the ability of bortezomib to deplete plasma cells, the
remaining memory B cells that were not affected by bortezomib
were reactivated in response to the challenge with AAV2/8-
DC190-alphaGal. These data also indicate that residual antibody
levels and the subsequent rapid production of large amounts of
anti-AAV-specific IgG blocked infection by the recombinant
AAV2/8-DC190-alphaGal vector and therefore the expression of
a-galactosidase A in the liver.
Discussion
AAV-mediated gene transfer is emerging as a platform for
treating a variety of disease indications. This increasing acceptance
is a result of the vector’s versatility at transducing various cell types
and its relatively attractive safety profile [18,23–27]. However, the
clinical deployment of AAV, particularly for treating diseases of
the viscera, is limited by the presence of pre-existing immunity
against the virus in the general population. Anti-AAV immunity
consists of two major components, specifically, humoral and
cellular, which limit the transduction efficiency of the virus and the
expression of the transgenes. A major contributor to the inhibition
of AAV-mediated transduction is the prevalence of neutralising
anti-AAV antibodies in humans due to their prior exposure to the
virus [6]. Cellular immune responses to the virus, mediated by
antigen-specific cytotoxic CD8
+ T cells, also eliminate virally
infected cells. In this study, bortezomib, a specific inhibitor of the
26 S proteasome that reportedly has multiple effects on cellular
and humoral immune responses [9], was evaluated for its ability to
attenuate pre-existing immunity to AAV. Although bortezomib
efficiently reduced the level of anti-AAV immunity, this effect was
insufficient to facilitate subsequent transduction by an AAV vector
of a similar serotype.
The 26 S proteasome is an essential component of the cytosolic
protein degradation machinery, which is involved in the turnover
of normally folded proteins and the degradation of misfolded
proteins [28]. Misfolded proteins trigger the so-called unfolded
protein response, which targets their removal by the proteasome
system. Because bortezomib efficiently inhibits the proteasome, it
can block unfolded protein response, thereby inducing cellular
apoptosis [29]. Plasma cells are terminally differentiated B cells
that secrete large amounts of IgG [20,30,31]. Because of this high
level of protein synthesis (increased occurrence of misfolded
proteins), plasma cells are hypersensitive to proteasome inhibitors,
such as bortezomib. This inhibitory property of bortezomib has
been demonstrated in a pre-clinical model of systemic lupus
erythematosus and in a clinical setting in the treatment of multiple
myeloma, which is a B cell-derived malignancy in which cancer
cells produce large amounts of secreted IgG [9,15,29,32]. In this
study, we examined whether this property of bortezomib could be
used to deplete anti-AAV antibody-producing cells. A reduction in
Figure 2. Bortezomib treatment reduces plasma cell levels in spleen and bone marrow. a. Mononuclear cells were prepared from spleen
and analysed for the B cell markers CD19, CD38, CD138, and CD27 using flow cytometry. Plots depict CD27 and CD138 expression gated on the
CD19
+ population. b. A summary of the data from a is shown in a quantitative format. c. Mononuclear cells that were isolated from bone marrow
were analysed for the B cell markers CD19, CD38, CD138, and CD27. Plots depict CD27 and CD138 expression gated on the CD19
+ population. d. A
summary of the data from c is shown in a quantitative format. The figures show representative data from two independent experiments with similar
outcomes.
doi:10.1371/journal.pone.0034684.g002
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recombinant AAV vector.
To mimic conditions in humans, mice were first exposed to a
recombinant AAV vector (AAV2/8-EV) to elicit the production of
high levels of anti-AAV antibodies. Treatment of these mice with
bortezomib reduced the titres of antibodies and the CD8
+
cytotoxic T cell responses. However, these beneficial effects were
insufficient to facilitate subsequent gene transduction after the
systemic administration of a second recombinant AAV vector
(AAV2/8-DC190-alphaGal). Following the administration of the
second vector, anti-AAV antibody levels rose rapidly, presumably
resulting from combination of residual antibody levels and the
reactivation and subsequent differentiation of AAV-specific
memory B cells. Consistent with this theory, a decrease in
CD138
+ plasma cells (but not memory B cells or other B-cell
populations) was detected following treatment with bortezomib.
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Figure 3. Bortezomib treatment differentially affects T cells. a. Mononuclear cells were prepared from spleens and analysed for the T cell
markers CD4, CD8, and CD44 using flow cytometry. Plots depict CD44 expression gated on the CD4
+ (left panel) and CD8
+ (right panel) populations.
b. A summary of the data from a is shown in a quantitative format. c. Mononuclear cells isolated from spleen were reactivated with AAV2/8-EV for
72 h in vitro. Supernatants were collected and assayed for IL-2 (left panel) or interferon-c (right panel) levels using ELISA. The figures show
representative data from two studies with similar outcomes.
doi:10.1371/journal.pone.0034684.g003
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PLoS ONE | www.plosone.org 6 April 2012 | Volume 7 | Issue 4 | e34684Figure 4. Bortezomib-mediated reduction in anti-AAV IgG titres is insufficient to facilitate reinfection with AAV2/8-DC190-
alphaGal. a. At twenty-four weeks following the administration of AAV2/8-EV (including 20 weeks of bortezomib treatment between weeks 4 and
24), mice were re-infected with 5610
11 AAV2/8-DC190-alphaGal/mouse vector particles. Sera were collected at the indicated times, and the titres of
anti-AAV IgG were determined. b. A subset of the sera samples was assayed for the total amount of IgG using ELISA. c. The level of a-galactosidase A
in serum samples from mice infected with AAV2/8-DC190-alphaGal. Expression of a-galactosidase A was observed in mice that had not been
previously infected with AAV2/8-EV. d. Immunohistochemistry was performed on liver sections from mice that were administered AAV2/8-DC190-
alphaGal. The figures show representative data from two studies with similar outcomes.
doi:10.1371/journal.pone.0034684.g004
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PLoS ONE | www.plosone.org 7 April 2012 | Volume 7 | Issue 4 | e34684This finding regarding the selectivity of bortezomib is congruent
with reports by Neubert et al [13]. Memory B cells have been
characterised as producers of IgG at lower levels; therefore, they
may be less sensitive to the action of proteasome inhibitors [20].
Although we surmise that residual antibody levels after bortezomib
treatment contributed significantly to the lack of ability to re-infect
mice with AAV2/8-DC190-alphaGal (as relatively low levels of
neutralizing anti-AAV antibodies are sufficient to block AAV
infection [33]), we do not believe that this was simply due to the
inability of the bortezomib treatment to reduce anti-AAV antibody
titres to a level below 8,000. In bortezomib-treated animals, there
was no difference in the kinetics of the increase in the anti-AAV
titre in the sera of mice following infection with AAV2/8-DC190-
alphaGal between the PBS- and bortezomib-treated groups
(Figure 4), thereby indicating that there was an active expansion
of the number of antibody-producing cells. The data shown in
Figure 4a also demonstrate that anti-AAV antibody levels rose
with significantly slower kinetics in previously naı ¨ve mice than in
animals previously exposed to AAV2/8-EV, indicating a primary
response in the previously naı ¨ve mice vs. a secondary memory
response in the previously AAV2/8-EV-infected animals. These
data suggest that bortezomib only affects B cells, such as plasma
cells, that are actively synthesising large amounts of IgG. It is also
important to point out that we observed bortezomib-related
toxicity in ,15% of animals treated with 1 mg/kg bortezomib,
whereas there was no measurable effect when we used 0.2 or
0.04 mg/kg bortezomib indicating that bortezomib displays a
narrow therapeutic window as a strategy to lower anti-AAV
immunity in the mouse strain we used (Figure 1a and data not
shown). Bortezomib also causes considerable side effects in human
subjects treated with this agent, although the therapeutic window
for clinical use may be very different [9,32]. Taking this into
consideration also guided the design of our studies to limit the
exposure of mice to bortezomib. A dose of 1.3–1.5 mg/m
2 body
surface area is typically used to address multiple myelomas in
human. This converts to approximately 0.04 mg/kg for a 60 kg
person. Using a biometrics conversion factor of 10:1 between
mouse and human [34], the human dose is roughly equivalent to
0.4 mg/kg in mouse. Thus, our effective dose at 1 mg/kg in
mouse approximates that used in the human setting; hence, the
clinical dose in human may be sufficient to reduce pre-existing
antibodies to various antigens. Yet, this dose led to toxicity in mice
which may be due to species-specific differences.
The sustained rise in antibody levels in both PBS- and
bortezomib-treated animals was somewhat unexpected. AAV
clears from circulation of mice 2–4 hours post tail vein injection
[35]. The fact that anti-AAV levels rise for weeks after
administration of AAV2/8-DC190-alphaGal suggests that anti-
gens from AAV may be retained for extended periods of time in
secondary lymphoid organs to activate B cell populations and once
again highlights the importance of depleting memory B cells that
home to secondary lymphoid organs in the interest of efficient
administration of vector.
Interestingly, although the antibody levels were similar in
bortezomib- and PBS-treated mice following the administration of
AAV2/8-DC190-alphaGal (Figure 4b), the number of CD138
+
plasma cells was lower in the bortezomib-treated mice than in the
PBS-treated mice (Figure 2a, left panel and Figure 2b, top row;
Figure 2c, left panel and Figure 2d, top row). This finding suggests
that re-activation of AAV-specific memory B cells did not cause
the cells to differentiate into CD138
+ plasma cells or that these
cells were not located in the anatomical locations examined. It is
also possible that the re-activated memory B cells differentiated
into a developmental stage that was still CD138
2. Additional
studies are needed to differentiate between these possibilities.
B cells have the capability to secrete IgG at many stages during
their development [31], and, because the bortezomib treatment
was discontinued at the time of re-infection, re-activated memory
B cells were not inhibited from producing AAV-specific IgGs. This
treatment regimen (i.e., not administering bortezomib during the
second infection with AAV2/8) was chosen because the primary
goal of this study was to evaluate bortezomib as a depleting agent
for IgG-producing plasma cells and to examine the effects of this
depletion on subsequent AAV infections. We designed our studies
to achieve this goal with the shortest exposure of mice to
bortezomib as possible (see above). Bortezomib treatment during
the second infection would have interfered with memory T cell-
mediated immune responses, which we believe would have
confounded the conclusions of the studies on the AAV-specific
plasma cells.
We designed our experiments to elicit strong immune responses
against AAV in mice by using a relatively high amount of AAV.
The dose we used has been routinely used for pre-clinical studies
in our previous studies [16–18]. Additionally, kinetics of anti-AAV
responses show similar kinetics to what we detected in our studies
at significantly lower doses of AAV (e.g. 10
10/mouse, reference
[36]). As a reference, the recently published clinical studies
targeting Factor IX deficiency in humans used a dose range of
2*10
11–2*10
12 vector genomes/kg [37]. We believe that the dose
we used in our studies approximates the doses used in this human
study taking into account conversion factors between mice and
humans [34]. Whether bortezomib would have shown better
efficacy at lower doses of initial AAV infection remains to be
determined as little is known about the effect of antigen dose on
B cell memory formation.
The administration of AAV2/8-DC190-alphaGal to mice that
were previously exposed to AAV2/8-EV did not cause measurable
expression of a-galactosidase A. This result is probably due to the
neutralisation of AAV2/8-DC190-alphaGal by the anti-AAV
humoral immune response. The lack of transgene expression was
not due to competition for transcription factors because the AAV
used in the first infection did not encode a transgene and
harboured a different promoter (the CMV promoter is used in
AAV2/8-EV, whereas the DC190 promoter is used in AAV2/8-
DC190-alphaGal). We also do not believe that the protocol of
prolonged bortezomib treatment itself interfered with re-infection
of mice with AAV2/8-DC190-alphaGal as bortezomib displays a
fast clearance rate (half-life in blood of bortezomib is ,8h
[38,39]) that is significantly shorter than the time period (3 days)
we allowed between the final bortezomib injection and re-infection
with AAV2/8-DC190-alphaGal.
Taken together, the data indicate that lowering pre-existing
immune responses against AAV to a level that will enable efficient
transduction by recombinant AAV vectors is likely to remain
challenging. The bortezomib-mediated reduction in the levels of
AAV-specific IgG was not sufficient to facilitate a repeat
transduction by a recombinant AAV2/8-based vector. Because
bortezomib has a narrow therapeutic window, a combination
therapy that includes additional B cell inhibitors, such as anti-
CD20 antibodies (e.g. Rituximab), may be required to reduce
efficiently the pre-existing humoral immunity to AAV. The data
presented here highlight the need to dramatically reduce the levels
of AAV-specific IgG and argue for the elimination of AAV-specific
memory B cells that have the capability to produce AAV-specific
antibodies upon re-activation. Further studies are needed to
evaluate the efficacy of a combination treatment that targets both
plasma and memory B-cell populations.
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